Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06764459

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

Status
Recruiting
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.

Detailed description

This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of single-cell molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment. In this way, it is possible to study how the mutational profile varies under therapeutic pressure and identify any alterations responsible for resistance. It will thus be possible to define a panel of new molecular markers to be included in the diagnostic routine to identify early patients refractory/resistant to treatment with FLT3 inhibitors and thus improve the therapeutic approach of these patients.

Conditions

Timeline

Start date
2023-03-15
Primary completion
2025-12-31
Completion
2026-12-31
First posted
2025-01-08
Last updated
2025-01-30

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06764459. Inclusion in this directory is not an endorsement.

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to (NCT06764459) · Clinical Trials Directory